

---

Product Manual

# LDL/VLDL Purification Kit (Ultracentrifugation Free)


Catalog Number

STA- 606

10 preps

**FOR RESEARCH USE ONLY**  
Not for use in diagnostic procedures

---




**CELL BIOLABS, INC.**

*Creating Solutions for Life Science Research*

## **Introduction**

Lipoproteins are submicroscopic particles composed of lipid and protein held together by noncovalent forces. Their general structure is that of a putative spheroidal microemulsion formed from an outer layer of phospholipids, unesterified cholesterol, and proteins, with a core of neutral lipids, predominately cholesteryl esters and triacylglycerols (TAG). Very low density lipoprotein (VLDL), a spherical particle with a diameter of 30-100 nm, is the major plasma vehicle for TAG and is the precursor to Low density lipoprotein (LDL). Each VLDL contains one molecule of a hydrophobic protein known as apolipoprotein B-100 (Apo B), as well as multiple copies of apolipoprotein E and apolipoprotein C (Figure 1 left).

LDL is the major transport protein for cholesterol in human plasma. LDL, like VLDL, is also a spherical particle with a diameter of 20-25 nm. Each LDL particle contains cholesteryl esters in its core which are surrounded by a hydrophilic coat composed of phospholipids, cholesterol, and one molecule apolipoprotein B-100 (Figure 1 right).



**Figure 1: Structure of VLDL (left) and LDL (right).**

The LDL/VLDL Purification Kit uses Dextran Sulfate to selectively precipitate LDL/VLDL from plasma or serum. The kit allows for the purification of LDL/VLDL without the need for ultracentrifugation. The lipoprotein particles are highly purified through a series of precipitation and low speed centrifugation steps. Each kit provides sufficient reagents to perform up to 10 preps, and each preparation can purify up to 10 mL of serum or plasma samples with a yield of ~600 µg of LDL/VLDL per mL for human samples (expected yield will vary by species).

## **Related Products**

1. STA-212: Malondialdehyde (MDA) Modified Human Low Density Lipoprotein (LDL)
2. STA-214: Copper (Cu<sup>++</sup>) Oxidized Human Low Density Lipoprotein (LDL)
3. STA-369: Human Oxidized LDL ELISA Kit (MDA-LDL Quantitation)
4. STA-389: Human Oxidized LDL ELISA Kit (HNE-LDL Quantitation)
5. STA-390: Total Cholesterol Assay Kit (Fluorometric)

6. STA-391: HDL and LDL/VLDL Cholesterol Assay Kit
7. STA-607: HDL Purification Kit (Ultracentrifugation Free)
8. STA-608: LDL/VLDL and HDL Purification Kit (Ultracentrifugation Free)

### **Kit Components**

1. Dextran Solution (Part No. 260601): One 0.6 mL vial
2. Precipitation Solution A (Part No. 260602): One 6 mL amber bottle
3. Bicarbonate Solution (Part No. 260803): One 4 mL bottle
4. 10X Precipitation Solution B (Part No. 260804): One 10 mL bottle
5. NaCl Solution (Part No. 260806): One 6 mL bottle containing 5% NaCl
6. 10X Precipitation Solution C (Part No. 260807): One 20 mL bottle
7. Dextran Removal Solution (Part No. 260608): One 1.6 mL vial

### **Materials Not Supplied**

1. Serum or Plasma Samples
2. PBS
3. Microcentrifuge or Centrifuge
4. 10  $\mu$ L to 1000  $\mu$ L adjustable single channel micropipettes with disposable tips

### **Storage**

Upon receipt store Dextran Removal Solution at room temperature. Store all other components at 4°C.

### **Preparation of Reagents**

- 1X Precipitation Solution B: Dilute the 10X Precipitation Solution B to 1X with deionized water. Stir to homogeneity. Store unused solution at 4°C.
- 1X Precipitation Solution C: Dilute the 10X Precipitation Solution C to 1X with deionized water. Stir to homogeneity. Store unused solution at 4°C.

## **Purification Protocol**

*Note: The purification protocol below is written for a 10 mL sample size. For smaller sample volumes, scale down each step proportionally.*

### **I. Dextran Precipitation**

1. To 10 mL of serum or plasma on ice, add 50  $\mu$ L of Dextran Solution and 500  $\mu$ L of Precipitation Solution A. Incubate 5 minutes on ice.
2. Spin at 6000 x g 10 minutes at 4°C.
3. Discard the supernatant. Use the remaining pellet which contains LDL and VLDL for section II below.

### **II. LDL/VLDL Purification**


1. Resuspend the pellet from section I above with 400  $\mu$ L of Bicarbonate Solution and spin at 6000 x g 10 minutes at 4°C.
2. Transfer the supernatant to a new tube. Discard the pellet.
3. Add 10 mL of 1X Precipitation Solution B to the supernatant. Mix thoroughly by pipetting up and down.
4. Spin at 6000 x g for 10 minutes at 4°C.
5. Discard the supernatant and resuspend the pellet with 200  $\mu$ L of NaCl Solution.
6. Add 10 mL of 1X Precipitation Solution C. Mix thoroughly by pipetting up and down.
7. Spin at 6000 x g for 10 minutes at 4°C.
8. Repeat steps 5-7.
9. Resuspend the pellet in 200  $\mu$ L of NaCl Solution (final volume about 500  $\mu$ L).
10. Add 80  $\mu$ L of Dextran Removal Solution. Mix thoroughly by pipetting up and down and incubate 1 hour at 4°C.
11. Spin at 6000 x g for 10 minutes at 4°C.
12. Recover the supernatant (purified LDL/VLDL) and transfer to a new tube.
13. Dialyze the purified LDL/VLDL in PBS and determine the protein concentration.

## Example of Results


The following figures demonstrate typical results with the LDL/VLDL Purification Kit. One should use the data below for reference only. This data should not be used to interpret actual results.




**Figure 2: SDS PAGE Gels of Purified Lipoproteins.** 20  $\mu\text{g}$  of LDL/VLDL purified by the STA-608 kit (lane 1) or ultracentrifugation (lane 2) was loaded on a 3-8% Tris Acetate Gel (A) or a 12% Bis Tris Gel (B) and stained with Coomassie Brilliant Blue Dye.



**Figure 3: Detection of Cholesterol in purified LDL/VLDL Samples.** Purified LDL/VLDL isolated using the LDL/VLDL and HDL Purification Kit (blue bars) or ultracentrifugation (red bars) was tested for the presence of Cholesterol using the Total Cholesterol Assay Kit (Cat. # STA-390).



**Figure 4: Detection of ApoA1 in purified Lipoprotein Samples.** Purified HDL or LDL/VLDL from the LDL/VLDL and HDL Purification Kit was tested for the presence of ApoA1 by ELISA.



**Figure 5: Detection of ApoB in purified Lipoprotein Samples.** Purified HDL or LDL/VLDL from the LDL/VLDL and HDL Purification Kit was tested for the presence of ApoB by ELISA.

## **References**

1. Atmeh R. F. (1990) *J Lipid Res*, **31**: 1771-1780.
2. Havel R.J. , Eder H.A., and Bragdon J.H. (1955) *J. Clin. Invest*, **34**: 1345-1353.
3. Gaubatz J.W., Chari M.V., Nava M.L, Guyton J.R., and Morrisett J.D. (1987) *J Lipid Res*, **28**: 69-79.
4. Kostner G.M., Ibovnik A., Holzer H., and Gillhofer H. (1999) *J Lipid Res*. **40**: 2255-2263.
5. Hirowatari Y., Yoshida H., Kurosawa H., Shimura Y., Yanai H., and Tada N. (2010) *J Lipid Res*. **51**: 1237–1243.
6. Lasser N.L., Roheim P.S., Edelstein D., and Eder H.A. (1973) *J Lipid Res*. **14**: 1-8.
7. Camus M-C., Chapman M.J., Forgez P., and Laplaud P.M. (1983) *J Lipid Res*. **24**: 1210-1228.

## **Recent Product Citations**

1. Boada, C.A. et al. (2021). LDL-Based Lipid Nanoparticle Derived for Blood Plasma Accumulates Preferentially in Atherosclerotic Plaque. *Front Bioeng Biotechnol*. **9**:794676. doi: 10.3389/fbioe.2021.794676.
2. Serkland, T.T. et al. (2019). Short communication: Distribution of psychotropic drugs into lipoproteins. *Ther Drug Monit*. doi: 10.1097/FTD.0000000000000660.
3. Charidemou, E. et al. (2019). A randomized 3-way crossover study indicates that high-protein feeding induces de novo lipogenesis in healthy humans. *JCI Insight*. **4**(12). pii: 124819. doi: 10.1172/jci.insight.124819.
4. Venkatakrisnan, K. et al. (2018). Comparative studies on the hypolipidemic, antioxidant and hepatoprotective activities of catechin-enriched green and oolong tea in a double-blind clinical trial. *Food Funct*. **9**(2):1205-1213. doi: 10.1039/c7fo01449j.
5. Ito, F. et al. (2017). The Application of a Modified d-ROMs Test for Measurement of Oxidative Stress and Oxidized High-Density Lipoprotein. *Int J Mol Sci*. **18**(2). pii: E454. doi: 10.3390/ijms18020454.
6. Smith, E. et al. (2016). Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. *Immunology* 1:eaah4081.

## **Warranty**

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS' sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.



## **Contact Information**

Cell Biolabs, Inc.  
7758 Arjons Drive  
San Diego, CA 92126  
Worldwide: +1 858-271-6500  
USA Toll-Free: 1-888-CBL-0505  
E-mail: [tech@cellbiolabs.com](mailto:tech@cellbiolabs.com)  
[www.cellbiolabs.com](http://www.cellbiolabs.com)

©2014-2023 Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.